Abstract
A randomised trial was initiated in Ireland in 1981 to determine if periconceptional supplementation with either folic acid alone or a multivitamin preparation alone could reduce the recurrence risk of neural tube defects (NTDs) in women with a previously affected pregnancy from 5 0% to 1-0% or less. The trial was concluded before the initial target number of study subjects was reached and without a cleartreatment effect being observed. A total of 354 women were randomised to receive one of three treatments: folic acid, multivitamins without folic acid, and folic acid plus multivitamins. At the end of the trial 257 women had had a first trial pregnancy outcome (261 infants/fetuses) where the presence or absence of NTDs was ascertainable. There was one NTD recurrence in the 89 infants/ fetuses of women in the multivitamin group and no recurrence in the 172 infants/fetuses of women in the folic acid groups, a nonsignificant difference. Otherwise eligible women who were pregnant when first contacted constituted a non-randomised control group; there were three recurrences among the 103 infants in this group. The difference in the recurrence rate between the folic acid groups and the non-randomised controls was statisticaily significant but we have reservations about the validity ofthis comparison. Although our findings do not provide clear evidence of a protective effect of folic acid supplementation they are consistent with those of the Medical Research Council (MRC) trial which demonstrated the efficacy of folic acid in preventing recurrence of NTDs and they raise the possibility that folic acid may be protective at a much lower dosage than that used in the MRC trial. ( Potential study subjects were identified by means of registers of cases of NTDs in participating hospitals. Eligible women were invited to discuss the trial and were given relevant information. Women who entered the trial gave verbal consent and were randomly allocated to one of three treatment groups: folic acid only (group F), multivitamins excluding folic acid (group M), and folic acid plus multivitamins (group FM). Random allocation was achieved by using consecutively numbered, opaque, sealed envelopes. Block randomisation was employed, 12 subjects per block, stratified by hospital.
TRIAL MEDICATION
The study was designed as a double blind trial. Beecham Pharmaceuticals (UK) initially provided similarly presented white multivitamin tablets without folic acid (Pregnavite Forte) and with folic acid (Pregnavite Forte F-as used by Smithells et al ' 4) . Glaxo (Ireland) Ltd manufactured a matched folic acid tablet. Although Beecham Pharmaceuticals (UK) initially agreed to supply the tablets for the full duration of the study their support was withdrawn one year later when 55 mothers had been randomised. Thereafter the commercially available Pregnavite Forte F (purple colour) was used and Antigen Pharmaceuticals produced a white multivitamin tablet without folic acid. It is felt that this partial loss of blinding did not materially affect the study outcome.
Trial participants were instructed to take one tablet three times daily for at least two months before conception and until the date of the third missed period. Compliance was based on tablet counts and blood tests but these results are not reported here. Tablets for women in the folic acid groups provided a daily dose of 0-36 mg of folic acid (0-12 mg/tablet). Tablets in the multivitamin groups provided daily doses of vitamin A 4000 IU, calciferol 400 Selected baseline data and pregnancy status at the end of the trial are presented for the three randomised groups and the non-randomised control group in table 1. When the trial ended in April 1990, 263 women who remained in the trial had completed a pregnancy, 16 women were not pregnant, and 75 had withdrawn from the study (table 1) . After withdrawal, 18 of the 75 women completed a pregnancy before the end of the trial, five becoming pregnant within six months of withdrawing (table 1) . Thus 281 randomised women had completed a pregnancy.
Seventy five women withdrew from the trial for the following reasons. Sixty six women said that they were no longer interested in a further pregnancy. The reasons given were: family or marital problems (n=7), fear of recurrence (n=7), advanced maternal age (n=4), and medical problems such as hysterectomy (n=5), No statistically significant differences between randomised groups. 'Randomised subjects v non-randomised controls: p<005.
results of Smithells et al' using a randomised design. Due to a marked fall over the study period in the number of eligible participants, it became necessary to end the trial prematurely without the initial target number of participants being reached and without a treatment effect being clearly established. There was one NTD recurrence in this trial which occurred in the non-folic acid group. There were no significant differences in recurrence between the randomised groups. With only one recurrence it is obviously difficult to draw any major conclusions. The difference in the recurrence rate between the folic acid groups and the non-randomised controls was statistically significant (p=002) but when the multivitamin only group (who did not receive folic acid supplementation) was combined with the non-randomised controls (who probably did not receive folic acid supplementation), the difference just failed to reach statistical significance (p=0Q06). This analysis is contingent on accepting the appropriateness of the statistical test used (see methods). Furthermore, as this is a comparison between a randomised group and a non-randomised control group, we feel that this finding should be interpreted with great caution. Despite our reservations these results are presented in view of the important question of high versus low dose folic acid in preventing NTDs. 12 The very low recurrence rate in the randomised women (O 4%) may have been due to self selection into the trial by women with a low recurrence risk. A comparison between the randomised women and the non-randomised controls for the risk factors for recurrence showed no consistent differences between the groups, although the control women had more previous births and were more likely to be in the lower social classes. Other confounding factors not investigated, for example, diet, may have contributed to the difference in recurrence rates. Baseline characteristics were similar for the three randomised groups, however.
Our findings are consistent with those of the MRC trial which demonstrated the efficacy of folic acid in preventing NTD recurrence.6 The absence of any NTD in the 169 women allocated to folic acid suggests that folic acid may also have been protective in our study. Should this be so, it raises the important consideration that folic acid may be protective at a daily dosage of 0-36 mg as used by us as well as at the much higher dosage of 4 If children and adolescents have a relatively high intake of calcium then peak bone mass (PBM) achieved in early adulthood is likely to be greater. If PBM is higher, then bone mass in later life is also likely to be higher and fractures in middle and old age less common.
If hip fractures occur in people with osteoporosis there may be an associated mortality of up to 20%.
If children develop a dietary habit it may persist when they are adults.
If people take more exercise, that too leads to them having a greater bone mass.
If the recommended dietary intake of calcium in childhood is increased will it be wholly beneficial.
If children take more calcium they are likely to do so by taking more milk. Would that be entirely a good thing?
If one of a pair of identical twins is given capsules of calcium citrate malate daily for three years and the other twin is given placebo then, provided they remain prepubertal at the end of the three years, the one given extra calcium will achieve a greater bone density (C Conrad Johnston Jr and colleagues, New England journal of Medicine 1992;327:82-7.
If I were a parent of twins I think I'd want to protect them from researchers.
If calcium is present in the human body with the same relative abundance as in the earth's crust and the ratios of the various isotopes of calcium in all things terrestrial were determined 4-5 billion years ago (Velimir Matkovic, leading article, New England Journal ofMedicine 1992;327:119-20) how could anybody top that as a piece of information?
ARCHIVIST If Rudyard Kipling is looking down from above I'mn sure he'll understand.
